Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the role of enzymatic processes in drug and toxin metabolism, emphasizing their impact on solubility and elimination, without presenting new clinical findings.

This article provides an overview of the indications, interactions, and various potential adverse reactions associated with several drugs, but it reports no specific new results.

This study found that JAK inhibitors effectively improve alopecia areata outcomes, as indicated by SALT scores, but they were associated with an increased risk of adverse effects, with 921 out of 1508 patients experiencing adverse reactions.

This study observed that Icariside II, an extract from Epimedium brevicornu Maxim, can inhibit the growth of gastric cancer in cell lines and mouse models by promoting apoptosis and suppressing the Wnt/β-catenin signaling pathway, with minimal toxicity to normal gastric cells.

In a reported case, researchers observed full hair regrowth on the scalp, eyebrows, and eyelashes of a 4-year-old with alopecia universalis after 10 months of treatment with dupilumab, following resistance to baricitinib.

This study reports new fluorogenic ceramidase substrates and highlights RBM14C24:1 as an efficient substrate for neutral ceramidase, while RBM15C18:1 is the best probe for measuring ACER1 and ACER2 activities, potentially aiding high-throughput screening for ceramidase inhibitors.

Water extract of cacumen platycladi helps hair growth by affecting specific cell pathways.

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

This review discusses the mechanism and side effects of smoothened inhibitors for advanced basal cell carcinoma, reporting no new clinical results and highlighting current management strategies for these adverse events.

In this study, researchers found that inhibiting inducible nitric oxide synthase (iNOS) promoted hair growth in diabetic mice, suggesting iNOS-derived nitric oxide contributes to hair loss under diabetic inflammatory conditions.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that longer exposure to 5α-reductase inhibitors significantly increased the risk of persistent erectile dysfunction, especially in younger men exposed to finasteride.

In this animal study, researchers found that finasteride may offer neuroprotective benefits as a post-ischemic treatment for strokes in aged male rats, suggesting its potential as a therapeutic agent in this context.

This study found that women with PCOS had significantly elevated plasma levels of PAI-1, which correlated with insulin resistance and obesity.

This study found that 5-alpha-reductase inhibitor monotherapy for symptomatic benign prostatic hyperplasia showed some clinical benefit over placebo but was linked to a higher incidence of sexual side effects.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study found that chi-miR-30b-5p was more expressed in the telogen phase than in the anagen phase and inhibited dermal papilla cell proliferation by targeting CaMKIIδ.

This study found no positive association between the use of 5α-reductase inhibitors and the risk of male breast cancer.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

This study found that high-concentration cell-free adipose extract effectively reduced collagen deposition and blood vessel formation in a rabbit ear model, showing promise for preventing and treating hypertrophic scars.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that finasteride treatment in male rats led to enduring effects on depressive-like behavior, hippocampal neurogenesis and neuroinflammation, and gut microbiota composition after withdrawal.

This study suggests that platelet-rich plasma's high levels of growth factors may be limited in promoting bone regeneration due to the concurrent release of Dickkopf-1, which inhibits osteogenesis.

This review discusses skin-related toxicities associated with targeted cancer therapies and emphasizes the need for dermatologists to understand and manage these adverse effects, but reports no new experimental results.

This article updates a prior work on pharmacophore modeling and highlights the advances in 3D database searching technologies for drug design, without presenting new research findings.

This study found that the Wnt inhibitor Dkk4 may play a role in regulating hair follicle development through a feedback loop with canonical Wnt signaling pathways.

This review discusses the presentation and management of skin toxicity from epidermal growth factor inhibitors, highlighting a correlation between cutaneous adverse effects and tumor response, but reports no new clinical results.

This research suggests that targeting the HIF-1α pathway via PHD inhibitors may enable regeneration similar to amphibians in mammals, potentially fast-tracking regenerative therapies from mice to humans.

This review highlights that while dexamethasone may reduce mortality in severe COVID-19, no other drugs have proven effectiveness for treatment, emphasizing the need for clinical trials of existing medications.